Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Recipharm AB","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recipharm Signs Agreement with Arcturus Therapeutics to Support the Manufacture of LUNAR[\u00ae]-COV19 (ARCT-021) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Recipharm AB"}]

Recipharm AB

Contact Supplier

Brightest Minds in the CDMO industry - From early Development to Commercial Manufacturing

Contact Supplier

Contact Supplier

Digital Content

Recipharm Signs Agreement with Arcturus Therapeutics to Support the Manufacture of LUNAR[®]-COV19 (ARCT-021) Vaccine Candidate

Details:

Arcturus has secured manufacturing slots with Recipharm to support the manufacture of ARCT-021, Arcturus’ COVID-19 vaccine candidate that is in an ongoing phase 1/2 clinical trial.

Lead Product(s): ARCT-021

Therapeutic Area: Infections and Infectious Diseases Product Name: LUNAR-COV19

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Arcturus Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 06, 2020

Recipharm Company Banner

CPhI Worldwide 2022

Booth # 90J30

envelop Contact Supplier

POST ENQUIRY